logo

Epix Pharmaceuticals, Inc. (EPIX)



Trade EPIX now with
  Date
  Headline
12/15/2017 10:57:38 PM ESSA Announces Filing Of Prospectus Supplement And An Update To Previously Announced Equity Offering
9/11/2017 7:47:11 AM EPIX Pharmaceuticals Trading Halted; Expected To Resume At 8:00 AM ET
9/11/2017 7:37:58 AM ESSA Pharma Announces Results From Phase 1 Clinical Trial Of EPI-506; Updates Clinical And Strategic Plans
9/7/2017 7:48:04 AM ESSA Pharma Announces Abstract Presentation On EPI-506 At European Society For Medical Oncology 2017 Congress
7/21/2017 7:34:41 AM ESSA Pharma Reports Receipt Of NASDAQ Notice Of Market Value Deficiency
7/20/2017 7:33:54 AM ESSA Pharma Announces Receipt Of NASDAQ Notice Of Bid Price Deficiency
7/18/2017 8:09:42 AM ESSA Pharma Reports Update To Proposed Equity Offering
7/12/2017 4:01:49 PM EPIX Pharmaceuticals Trading Halted Pending News
5/15/2017 7:54:36 AM ESSA Pharma Q1 Net Loss Of $7.61 Mln Or $0.26/shr Vs. Net Loss Of $1.05 Mln Or $0.04/shr Prior Year
4/5/2017 8:33:48 AM ESSA Pharma Receives $1.2 Mln Grant Payment From Cancer Prevention Research Institute Of Texas
4/3/2017 8:38:57 AM ESSA Pharma Updates On Status Of Phase 1 Clinical Study Of EPI-506 For Patients With MCRPC
12/14/2016 8:34:20 AM ESSA Pharma Q4 Net Loss $4.2 Mln Vs. Net Income $0.5 Mln Last Year
11/21/2016 8:33:37 AM ESSA Pharma Secures $10 Mln Growth Capital Term Loan Facility From Silicon Valley Bank
8/12/2016 4:01:21 PM ESSA Pharma Q3 Loss Per Share C$0.13 Vs Loss C$0.29 Last Year
8/1/2016 8:16:37 AM ESSA Pharma Appoints Peter Virsik As EVP And COO
1/7/2016 7:48:26 AM ESSA Pharma Appoints David Parkinson As President And CEO, Effective Immediately, Replacing Bob Rieder
12/14/2015 7:41:32 PM ESSA Pharma Q4 Net Income C$0.1 Mln Vs. Net Loss C$1.6 Mln Prior Year
11/5/2015 8:19:14 AM ESSA Pharma Receives Health Canada Approval To Commence Clinical Development For EPI-506
10/22/2009 3:11:31 PM Joseph Finn Assignee For Benefit Of Creditors Of EPIX Pharma Releases Statement Regarding Liquidation Process
  
 
>